Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38
网页2015年5月20日 · IMMU-132 treatment of mice bearing human gastric cancer xenografts (17.5 mg/kg; twice weekly × 4 weeks) resulted in significant antitumor effects compared to that of mice treated with a nonspecific control.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple …
网页2019年2月20日 · Sacituzumab govitecan-hziy (IMMU-132; Immunomedics) is an antibody–drug conjugate in which SN-38 (an active metabolite of irinotecan), a topoisomerase I inhibitor, is coupled to the...
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
网页2021年4月21日 · A phase 1–2, single-group, basket trial (IMMU-132-01) evaluated sacituzumab govitecan monotherapy in metastatic, epithelial cancers. 21-23 In the cohort of 108 patients with metastatic triple...
Sacituzumab govitecan - Wikipedia
网页Sacituzumab govitecan-hziy was approved based on the results of IMMU-132-01, a multicenter, single-arm clinical trial (NCT01631552) of 108 participants with metastatic triple-negative breast cancer who had received at least two …
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 ... - PubMed
网页2017年10月1日 · Background: Sacituzumab govitecan (IMMU-132), an antitrophoblastic cell-surface antigen (anti-Trop-2) humanized antibody-SN-38 conjugate, had encouraging efficacy in the phase 1 clinical trial. This report further examines the pharmacokinetics and safety of multiple cycles of IMMU-132 at doses of 8 or 10 mg/kg in patients with diverse …
Overall survival with sacituzumab govitecan in hormone receptor ...
网页2023年10月21日 · Sacituzumab govitecan was initially evaluated in HR+ and HER2– metastatic breast cancer in the phase 1–2 single-arm IMMU-132-01 study (NCT01631552) and showed encouraging activity with a safety profile consistent with previous reports.
FDA Approval Summary: Accelerated Approval of Sacituzumab …
网页2021年4月1日 · Results from the IMMU-132-01 trial demonstrated a favorable benefit–risk profile for sacituzumab govitecan with an improved ORR and DoR over available therapies.
FDA grants accelerated approval for sacituzumab govitecan
网页2021年4月13日 · Efficacy and safety were evaluated in TROPHY (IMMU-132-06; NCT03547973), a single-arm, multicenter trial that enrolled 112 patients with locally advanced or mUC who received prior treatment...
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 …
网页2017年5月30日 · Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting SN-38 to Trop-2 (an antigen identified in many epithelial cancers), is exhibiting promising activity in several indications. The...
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 …
网页2015年4月27日 · IMMU-132 treatment of mice bearing human gastric cancer xenografts (17.5 mg/kg; twice weekly × 4 weeks) resulted in significant antitumor effects compared to that of mice treated with a nonspecific control.